Similarly, administration of the BAC regimen for patients with primary grade 4 gliomas was beneficial for those with IDH-wild-type and MGMT-unmethylated gliomas in terms of both OS and PRS, revealing substantial findings (Figure 3, Supplementary Figure S4). The gene discussed is MGMT; the disease is glioma.